Novavax, Canada and COVID-19
Canada not ordering Novavax protein-based COVID vaccine this year due to low demand
TORONTO — The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus season, citing lack of demand. It says the manufacturer requires a minimum order of its updated protein-based vaccine, called Nuvaxovid, which far exceeds the uptake by Canadians last year.
The FDA recently approved the updated mRNA Pfizer and Moderna boosters, as well as the updated Novavax COVID vaccine, to ...
One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...
Novavax (NASDAQ:NVAX) shares fell ~3% in the premarket on Thursday after the company issued a clarification on an analyst ...
The Canadian Press on MSN4d
‘I have no options’: Canadians criticize lack of Novavax COVID shotThe federal government's decision to not provide Novavax's COVID-19 vaccine this respiratory virus season raises health equity concerns, experts and advocates say.
Although Pfizer's and Moderna’s COVID-19 vaccines have been stealing the spotlight for years, some people are actively seeking out the lesser-known Novavax for their updated booster this fall.
Novavax (NVAX) shares climbed 15% Wednesday after Jefferies released a bullish note on the company’s prospects after meeting ...
Novavax stock remains volatile. After hitting a two-year high in June on enthusiasm for its updated Covid vaccine, shares have pulled back. Recently, Zacks.com users have been paying close ...
The mRNA-based supplier of vaccines profited from Covid-19 vaccine sales. As the years passed, Covid evolved. The weaker ...
Novavax's financial position improved significantly with a $570 million cash infusion from Sanofi. Find out why I remain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback